Celyad Oncology SA (CYAD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

MDxHealth SA

argenx SE

BioSenic SA

DMS Imaging SA

Celyad Oncology SA

Why is Celyad Oncology SA ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Celyad Oncology SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Celyad Oncology SA

-44.83%

-0.89

110.31%

Belgium BEL 20

10.33%

0.57

17.97%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.37%

EBIT Growth (5y)

12.45%

EBIT to Interest (avg)

-21.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.78

Sales to Capital Employed (avg)

0.03

Tax Ratio

2.28%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-4.62

EV to EBIT

-2.02

EV to EBITDA

-2.16

EV to Capital Employed

-3.57

EV to Sales

13.61

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at EUR -15.82 MM

NET PROFIT(HY)

Higher at EUR -3.67 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 3.42 times

DEBTORS TURNOVER RATIO(HY)

Highest at 0.2 times

-4What is not working for the Company

ROCE(HY)

Lowest at -7,870.73%

RAW MATERIAL COST(Y)

Grown by 56.69% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -1.32 %

Here's what is working for Celyad Oncology SA

Operating Cash Flow

Highest at EUR -15.82 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (EUR MM)

Net Profit

Higher at EUR -3.67 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (EUR MM)

Inventory Turnover Ratio

Highest at 3.42 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 0.2 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Celyad Oncology SA

Debt-Equity Ratio

Highest at -1.32 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 56.69% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales